ArticleAnnals of surgical oncology2026
Breast-Conserving Surgery Versus Mastectomy After Neoadjuvant Therapy: A Survival Analysis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer management has increasingly incorporated neoadjuvant therapy (NAT), particularly to improve rates of pathologic complete response (pCR) and expand eligibility for breast-conserving surgery (BCS) instead of mastectomy. Using SEER database data, we evaluated whether BCS versus mastectomy after NAT is associated with different survival outcomes in patients with pCR. PATIENTS AND
methodsWe performed a population-based study including women with nonmetastatic invasive breast cancer diagnosed between 2010 and 2015 who received NAT followed by BCS or mastectomy and achieved pCR. Overall survival (OS) and breast-cancer-specific survival (BCSS) were assessed using unadjusted and multivariable Cox regression models. To reduce treatment selection bias, propensity score matching and inverse probability of treatment weighting (IPTW) were applied.
resultsAmong 2749 patients, 1703 (62%) underwent mastectomy and 1046 (38%) BCS. Patients treated with mastectomy more often had larger tumors, greater nodal burden, and less favorable baseline characteristics. After a median follow-up of 110 months, 384 deaths and 265 breast-cancer-specific deaths were recorded. In unadjusted analyses, BCS was associated with improved OS (hazard ratio (HR) 0.62, 95% CI 0.50-0.78; p > 0.001) and BCSS (HR 0.47, 95% CI 0.35-0.63; p > 0.001). These associations remained significant after multivariable adjustment (OS: HR 0.67, p = 0.002; BCSS: HR 0.55, p > 0.001), propensity score matching (OS: HR 0.70, p = 0.02; BCSS: HR 0.48, p > 0.001), and IPTW (OS: HR 0.64, p = 0.005; BCSS: HR 0.58, p = 0.008).
conclusionsIn patients with pCR, BCS after NAT was not associated with inferior survival compared with mastectomy and was consistently associated with better OS and BCSS across all analytical approaches.
Indexed as
Identifiers
42706469What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.